Access Biotechnology — Full Portfolio
34 tracked investments · listed companies and verified rows first
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Hendersonin
Co-investorsRA Capital
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)in
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)inTim Shannon(Director)inKush Parmar(Director)
Co-investors5AM VenturesCanaan PartnersConnecticut InnovationsNextech InvestRA CapitalSolasta Ventures+1 more
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)
BoardChristopher Cain(Director)Carl Goldfischer(Director)Peter Harwin(Director)
Co-investorsBay City CapitalEIR Ventures
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed5AM Ventures+6 more
BiotechWilmington, US
Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)
BoardAdam Rosenberg(Director)
Co-investorsManta Ray VenturesACORN BIOVENTURESRA Capital
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsHealthCapNovo HoldingsSofinnova Partners
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inNicholas Saccomano(Executive Officer, Director)Wendy Johnson(Executive Officer)
BoardIsaac Manke(Director)in
Co-investorsBoulder VenturesRiverVest Venture PartnersAbingworthACORN BIOVENTURESNew Enterprise Associates (NEA)
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)
BoardPatrick Heron(Director)inCarl Gordon(Director)Thomas Street Address 1 Woiwode(Director)Saqib Islam(Director)
Co-investorsFrazier Life SciencesFrazier Healthcare PartnersNew Leaf Venture PartnersOrbiMedVersant VenturesVivo Capital
Spyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.
BiotechHealthtechMedical Devices
Co-investorsAisling Capital
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesBain Capital Life SciencesDecheng CapitalSamsara BioCapitalTCG Crossover+1 more
Zura Bio is a clinical-stage biotechnology company developing antibody therapies for autoimmune diseases using a dual antagonism strategy that targets multiple immune pathways simultaneously.
BiotechHealthtechLa Jolla, US
Someit Sidhu(Executive Officer, Director)inMuzammil Mustufa(Chief Business Officer)inKiran Nistala(Chief Medical Officer and Head of Development)inNeil Graham(Director)Gary Whale(Chief Technology Officer)Garry Neil(Director)
Co-investorsTMG Ventures
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.
BiotechDeep TechDigital HealthMedical DevicesCardiff, GB
John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in
Co-investorsCanaan PartnersSanofi VenturesSV Health InvestorsSR One Capital ManagementBritish Business BankJanus Henderson Investors
Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.
AI & Machine LearningBiotechHealthtechAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)inAnsuman Satpathy(Scientific Founder)inNewman Yeilding(Chief Medical Officer)in
Co-investorsVersant VenturesAndreessen HorowitzGV (Google Ventures)RTW Investments L.P.TPG
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)inSchalon Newton(Executive Officer)in
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsExSight VenturesHatteras Venture PartnersSolasta VenturesBios PartnersCorrelation VenturesFemHealth Ventures+2 more
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)Jorge Bartolome(Executive Officer, Director)
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Co-investorsARCH Venture PartnersBain Capital Life SciencesGV (Google Ventures)Maverick CapitalSaturn PartnersViking Global Investors
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)Daniel Becker(Director)
Co-investorsAtlas VentureCanaan PartnersRA CapitalThe Column Group
Co-investorsAvoro Capital Advisors
A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.
BiotechDigital HealthHealthtech
Co-investorsBain Capital Life Sciences
The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.
BiotechHealthtechSan Diego, US
Arthur T Suckow(Executive Officer)inArthur Suckow, Ph.D.(Founder)in
Co-investorsExSight VenturesRA CapitalJanus Henderson Investors
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)in
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in
Co-investorsCanaan PartnersConnecticut InnovationsFrazier Life SciencesRA CapitalTaiho Ventures, LLCVida Ventures
Khanda is a biotech company builder that translates validated and emerging biological insights into new biotechnology companies focused on orthogonal, combination-based therapeutic approaches.
Biotech
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Deborah Palestrant(Director)inKevin Raidy(Director)
Co-investorsForesite CapitalKern Capital, LLCSanofi Ventures5AM VenturesWestlake Village BioPartners
Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureNextech InvestForbionRA Capital
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)Bruce Booth(Director)Daniel Becker(Director)
Co-investorsDigitalis VenturesSanofi Ventures
Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
Co-investorsBain Capital Life SciencesLightstone VenturesPfizer Venture InvestmentsRA CapitalSV Health Investors
BiotechCambridge, US
Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)inAnthony Coyle(Executive Officer, Director)Christopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)
Co-investorsPolaris PartnersVersant Ventures
Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.
BiotechHealthtechMedical DevicesSan Francisco, US
Sevgi Gurkan, MD(Founder, Chief Executive Officer, and Member of the Board of Directors)in
BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in
Co-investorsOrbiMedCatalio Capital Management, LPHatteras Venture PartnersLAVLilly Asia VenturesHatteras
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)
BoardPETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsMission BiocapitalSofinnova VenturesMission Bay CapitalNew Leaf Venture PartnersOrbiMedSamsara BioCapital
Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
Nancy Whiting(CEO)in
Co-investorsNew Enterprise Associates (NEA)Westlake Village BioPartners
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.
BiotechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)inAnsuman Satpathy(Scientific Founder)in
BoardThomas Woiwode(Director)in
Co-investorsAndreessen HorowitzGV (Google Ventures)Versant Venture CapitalVersant Ventures
Surrozen develops multifunctional biologic therapies that selectively activate Wnt signaling to address ophthalmic diseases with unmet medical needs.
BiotechHealthtechMedical Devices
Co-investorsThe Column Group
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)Sofinnova Partners+4 more
Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.
BiotechHealthtechMedical Devices
Bernard Ravina(Founder and Chief Executive Officer)inJudy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)inAriel D. Jasie(Chief Business Officer and General Counsel)inTushar Misra(Chief Technical Officer)in
Co-investorsAtlas VentureFrazier Life SciencesAccess IndustriesCanaan Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.